儿童医院和科罗拉多州医学科罗拉多大学法学院

Ventria Bioscience has been engaged in a multi-year collaboration with the research group of Edwin de Zoeten, MD, PhD (Children’s Hospital Colorado and University of Colorado School of Medicine) to investigate the mechanisms by which Ventria’s lead candidate, VEN120—the principal component of which is lactoferrin—reduces inflammation in preclinical models of inflammatory bowel disease (IBD).